Amarin To Acquire Ester Neurosciences, Gain Clinical-Stage Neuromuscular Drug
This article was originally published in The Pink Sheet Daily
Amarin CEO Stewart tells “The Pink Sheet” DAILY about the company’s partnering strategy for neurology and cardiovascular drugs.
You may also be interested in...
London firm aims to substantiate the effectiveness of the neuroprotector in a genetic subgroup of Huntington's patients.
Pharma giant gains control over Coley’s Toll-like receptor patent estate and next-generation vaccine adjuvants with $164 million acquisition.
Jessica O’Connell, partner at Covington & Burling, is getting questions from clients about the electronic system the FDA plans to launch in coming weeks for cosmetics manufacturers to register facilities and list products as required by new cosmetics regulations. It remains to be seen how hard the 29 December 2023 deadline will be for companies to get their information submitted.